Overseeing Opioid Use in Your Facility



Dr. Steven A. Levenson, MD, CMD

January 4, 2023



Quality Innovation Network -Quality Improvement Organizations CENTER S FOR MEDICARE & MEDICAI D SERVICES IQUALITY IMPRO VEMENT & INNOVATION GROUI

Steven Levenson, MD, CMD

Steven Levenson, MD, CMD, has spent 43 years providing and overseeing long-term and post-acute care. He has been a medical director in 22 different nursing homes in Maryland and has reviewed and guided the care of thousands of patients in facilities in 28 states. He has authored or co-authored more than 80 articles and four books on medical direction, subacute care, quality improvement and many other topics.

Between 1988 and 2013, he was extensively involved with CMS in developing and refining various aspects of the OBRA process, including surveyor guidance, the MDS, and training materials for surveyors and facilities. This included several updates to the Unnecessary Drugs guidance, including those related to psychopharmacologic medications. He also recently chaired the workgroup that revamped the AMDA Pain CPG.



Tanya Vadala, PharmD

MEDICATION SAFETY PHARMACIST

Tanya is an IPRO pharmacist with 18 years of clinical pharmacy, community pharmacy, academia, quality improvement and medication safety experience. Prior to joining IPRO, she worked at various community pharmacies and taught at the Albany College of Pharmacy and Health Sciences in Albany, N.Y. She specializes in medication therapy management (MTM), medication reconciliation, opioids, immunizations and patient self-care. Her formal teaching experience includes courses in pharmacy practice and clinical experiential teaching.

Contact: <u>TVadala@ipro.org</u>



Making Health Care Better Together

About Alliant Health Solutions



Objectives

- Have a meaningful and useful tool to review opioid-related considerations in your facility
- Identify how to use an oversight tool in your facility
- Identify how to involve your medical practitioners and medical director in supporting appropriate opioid use



The Care Delivery Process

- Assessment/Problem Definition
- Diagnosis/Cause Identification
- Selecting and Ordering Treatments
- Monitoring



Assessment/Problem Definition

- Details of pain (including a detailed description, exact location, and frequency, intensity, duration) identified and documented
- Patient **screened** carefully for evidence of opioid dependency/addiction
- Clinically pertinent **rationale** is **documented** for why opioids are indicated for the type, nature and location of pain



Cause Identification

• Pertinent causes of pain (including medication-related adverse consequences) are investigated and either *ruled* out or identified and documented



Selecting and Ordering Treatments

- **Realistic goals** for pain and function set, based on diagnosis and prognosis
- Reasonable and relevant non-opioid therapies tried and optimized
- **Benefits and risks** of opioid treatment reviewed realistically with patient/family, as feasible
- **Cause-specific interventions** identified, ordered, and documented



Selecting and Ordering Treatments

- IF opioids are indicated, then short-acting opioids are prescribed using the lowest dosage on product labeling
- ANY ongoing long-acting opioids are used ONLY with documented rationale as to why a continuous dose of opioids is medically necessary



Selecting and Ordering Treatments

- Fentanyl is used very sparingly and only for individuals who need a continuous dose of medication that is 100 times more potent than morphine, with detailed, documented rational
- **Benzodiazepines** (lorazepam, clonazepam, alprazolam, etc.) are not given concurrently with opioids unless a clear and compelling clinically pertinent rationale based on medical necessity is documented for using both together



Monitoring

- Need for continuing opioids for ANY reason is reviewed and documented at each scheduled reassessment
- Adequately detailed **evaluation to confirm** that patient has clinically meaningful *improvements* in pain and function without significant risks or harm
- At revisit, **opioids are only continued after confirming** 1) clinically meaningful *improvements* in pain and function, 2) *without significant risks or harm,* AND 3) a clearly identified reason why tapering or stopping is contraindicated
- Tapering of opioids done correctly and safely



Monitoring

- Pertinent rationale is always documented for any longacting opioids, including reasons for the inadequacy of non-opioid alternatives or shorter-acting opioids
- Observations made and documented regarding adverse consequences such as signs of oversedation or overdose risk, falls, anorexia, or increasing confusion and behavior issues
- Verification that non-opioid approaches have been implemented and optimized







Nursing Home and Partnership for Community Health: CMS 12th SOW GOALS







Promote opioid best practices

Reduce opioid adverse drug events in all settings PATIENT SAFETY

Reduce hospitalizations due to c. diff

> Reduce adverse drug events

Reduce facility acquired infections



CHRONIC DISEASE SELF-MANAGEMENT

Increase instances of adequately diagnosed and controlled hypertension

Increase use of cardiac rehabilitation programs

Reduce instances of uncontrolled diabetes

Identify patients at highrisk for kidney disease and improve outcomes



CARE COORDINATION

Convene community coalitions

Reduce avoidable readmissions, admissions to hospitals and preventable emergency department visits

Identify and promote optimal care for super utilizers



COVID-19

Support nursing homes by establishing a safe visitor policy and cohort plan

Provide virtual events to support infection control and prevention

Support nursing homes and community coalitions with emergency preparedness plans



IMMUNIZATION

Increase influenza,

pneumococcal,

and COVID-19

vaccination rates



TRAINING

Encourage completion of infection control and prevention trainings by front line clinical and management staff



Scan the QR code or Click the Link to Complete the Assessment!

CMS requested Alliant Health Solutions, your QIN-QIO, to work with select nursing homes to understand emerging healthcare needs in nursing homes. Alliant Health Solutions is engaging nursing home leadership on each of these key areas to ensure plans are in place to achieve and maintain health quality and equity!

Please scan the QR code below and complete the assessment.



TRAINING

Encourage completion of infection control and prevention trainings by front line clinical and management staff



Nursing Home Infection

Prevention (NHIP) Initiative Training Assessment

https://bit.ly/NHIPAssessment



Making Health Care Better Together



Julie Kueker Julie.Kueker@AlliantHealth.org Alabama, Florida and Louisiana



Leighann Sauls Leighann.Sauls@AlliantHealth.org Georgia, Kentucky, North Carolina and Tennessee



Program Directors

ALABAMA • FLORIDA • GEORGIA • KENTUCKY • LOUISIANA • NORTH CAROLINA • TENNESSE



This material was prepared by Alliant Health Solutions, a Quality Innovation Network – Quality Improvement Organization (QIN – QIO) under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication No. 12SOW-AHS-QIN-QIO TO1-NH--2989-12/15/22

